HB 220 KY

0likes☆Favorite🔕SubscribeShare

Became Law

Amend KRS 304.17A-163 to permit insurers to require insureds to try biosimilar biological products prior to providing coverage for the equivalent branded prescription drug under certain circumstances; make findings and establish intent of Act.

• A. Neighbors Republican · primary
• D. Bentley · primary
• B. Chester-Burton Democratic · primary
• D. Lewis Republican · primary
• M. Pollock Republican · primary

1. Jan 10, 2024 introduced in House · lower
2. Jan 10, 2024 to Committee on Committees (H) · lower
3. Jan 24, 2024 to Health Services (H) · lower
4. Jan 25, 2024 reassigned to Banking & Insurance (H) · lower
5. Jan 31, 2024 reported favorably, 1st reading, to Calendar with Committee Substitute (1) and Committee Amendment (1-title) · lower
6. Feb 1, 2024 2nd reading, to Rules · lower
7. Feb 1, 2024 posted for passage in the Regular Orders of the Day for Friday, February 02, 2024 · lower
8. Feb 2, 2024 3rd reading, passed 91-0 with Committee Substitute (1) and Committee Amendment (1-title) · lower
9. Feb 5, 2024 received in Senate · upper
10. Feb 5, 2024 to Committee on Committees (S) · upper
11. Feb 22, 2024 to Banking & Insurance (S) · upper
12. Feb 27, 2024 reported favorably, 1st reading, to Calendar · lower
13. Feb 28, 2024 2nd reading, to Rules · lower
14. Mar 6, 2024 posted for passage in the Regular Orders of the Day for Thursday, March 07, 2024 · lower
15. Mar 7, 2024 3rd reading, passed 37-0 · lower
16. Mar 8, 2024 received in House · lower
17. Mar 8, 2024 enrolled, signed by Speaker of the House · lower
18. Mar 8, 2024 enrolled, signed by President of the Senate · upper
19. Mar 8, 2024 delivered to Governor · lower
20. Mar 14, 2024 signed by Governor (Acts Ch. 4) · lower

The published texts of this bill as it moves through the legislature. Each links to the official document on the state legislature site. Data from OpenStates.

• Acts Chapter 4 · PDF
• Current/Final · PDF
• Introduced · PDF